Shareholders were pleased with Ligand Pharmaceuticals' recent earnings report, but caution is advised due to share dilution impacting earnings per share. Net income increased, but EPS growth was less impressive, affected by dilution and unusual items boosting profit. Analysts' future profitability estimates should be considered.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing